Gene Therapy Market Research Report - Forecast till 2027

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo), Indication (Oncology, Genetic Diseases) and End-User (Hospitals & Clinics, Specialty Treatment Centers) - Forecast to 2027

ID: MRFR/HC/6927-HCR | February 2021 | Region: Global | 111 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Gene Therapy Market Forecast


Gene Therapy Market was valued USD 524 million in 2018 and expected to register a CAGR of 40.7% By 2025.


Market Synopsis


The research and development, along with increased investment in product development is driving the gene therapy market.


Market Influencer


Acquisitions of small-scale companies by key players and a large number of ongoing clinical trials are driving the gene therapy market.


Market Drivers



  • Robust product pipeline

  • Increasing investment by key players

  • High prevalence of target diseases and demand for innovative medication


Market Restraints



  • The high cost of product development

  • Stringent regulatory policies


Segmentation


By Product



  • Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018.

  • Luxturna: Luxturna is an Adeno Associated Virus (AAV) gene therapy for the treatment of retinal dystrophy.

  • Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.

  • Zolgensma: The brand Zolgensma has received provisional approval by the FDA for investigational product AVXS-101 (onasemnogene abeparvovec-xxxx).

  • Strimvelis: The drug is indicated for the treatment of severe combined immunodeficiency arising due to adenosine deaminase deficiency (ADA-SCID).

  • Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million.

  • Imlygic: It is the first oncolytic viral therapy

  • Others: This segment includes drugs which are ongoing pre-clinical or clinical trials.


By Indication



  • Oncology: The fastest-growing segment, due to the increasing prevalence of various types of cancer.

  • Genetic Diseases/ Disorders: The largest segment, due to the high number of approved products.

  • Others: Includes drugs, which are in Phase-3 of clinical trials, for indications like X-Linked Retinitis Pigmentosa, Hemophilia B, Leber Hereditary Optic Neuropathy, and Mucopolysaccharidosis Type IIIA amongst others.


By End-User



  • Hospitals & Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals.

  • Specialty Treatment Centers: A small segment, these centers provide treatments for specific diseases, for instance, cancer.

  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: The largest regional market, due to the presence of key market players and high healthcare expenditure



  • Europe: The growth of this region is due to product launches by key players.



  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of people affected with diseases and rising awareness about gene therapy.



  • Middle East & Africa: The smallest market due to limited healthcare infrastructure.


Key Players



  • Amgen, Inc. (US)

  • Novartis AG (Switzerland)

  • Spark Therapeutics, Inc. (US)

  • Gilead Sciences, Inc. (US)

  • uniQure N.V. (Netherlands)

  • Orchard Therapeutics plc (UK)

  • Celgene Corporation (US)

  • Bristol-Myers Squibb Company (US)

  • Thermo Fisher Scientific Inc. (US)

  • CEVEC (Germany)

  • Lonza (Switzerland)



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 524 Million
  • 2027: Significant Value
  •   CAGR   40.7% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Product, Indication, End-User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), Lonza (Switzerland)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Robust product pipeline
  • Increasing investment by key players
  • High prevalence of target diseases and demand for innovative medication


  • Frequently Asked Questions (FAQ) :


    Based on product, Gene therapy industry divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others. Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018. Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million. Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.

    The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. In the regional market Asia-Pacific is expected to be the fastest-growing market. On the basis of Indication The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

    The gene therapy market had reached a valuation of USD 524 MN in 2018.

    The gene therapy market is projected to grow at approximately 40.7% CAGR during forecast period (2019-2025).

    Rising technological advances and favorable government initiatives.

    North America holds the largest share in the gene therapy market, followed by Europe and the Asia Pacific, respectively.

    Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.